Metabolic features of clear-cell renal cell carcinoma: mechanisms and clinical implications

被引:47
|
作者
Pinthus, Jehonathan H. [1 ]
Whelan, Kaitlyn F. [1 ]
Gallino, Daniel [1 ]
Lu, Jian-Ping [1 ]
Rothschild, Nathan [1 ]
机构
[1] McMaster Univ, Dept Surg, Div Urol, Hamilton, ON L8S 4L8, Canada
来源
关键词
FATTY-ACID SYNTHASE; POSITRON-EMISSION-TOMOGRAPHY; KIDNEY CANCER; ACYL-COENZYME; FDG PET; HYPOXIA; PATHWAY; RISK; CHOLESTEROL; EXPRESSION;
D O I
10.5489/cuaj.10196
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Central to the malignant behaviour that endows cancer cells with growth advantage is their unique metabolism. Cancer cells can process nutrient molecules differently from normal cells and use it to overcome stress imposed on them by various therapies. This metabolic conversion is controlled by specific genetic mutations that are associated with activation of oncogenes and loss of tumour suppressor proteins. Understanding these processes is important as it can lead to the discovery of biomarkers that can predict the aggressiveness of the disease and its response to therapy, and even more importantly, to the development of novel therapeutics. A classic tumour in this respect is clear-cell renal cell carcinoma (RCC). In this review, we will begin with a brief summary of normal cellular bioenergetic pathways, which will be followed by a description of the characteristic metabolism of glucose and lipids in clear-cell RCC cells and its clinical implications. Data relating to the potential effect of dietary nutrients on RCC will also be reviewed along with potential therapies targeted at interrupting specific metabolic pathways in clear-cell RCC.
引用
收藏
页码:274 / 282
页数:9
相关论文
共 50 条
  • [21] Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase
    Kinnaird, Adam
    Dromparis, Peter
    Saleme, Bruno
    Gurtu, Vikram
    Watson, Kristalee
    Paulin, Roxane
    Zervopoulos, Sotirios
    Stenson, Trevor
    Sutendra, Gopinath
    Pink, Desmond B.
    Carmine-Simmen, Katia
    Moore, Ronald
    Lewis, John D.
    Michelakis, Evangelos D.
    EUROPEAN UROLOGY, 2016, 69 (04) : 734 - 744
  • [22] Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma
    Hugues, Marion
    Nerich, V
    Nai, T.
    Paillard, M. J.
    Borowski, L.
    Stein, U.
    Hon, Nguyen Tan T.
    Montcuquet, P.
    Maurina, T.
    Mouillet, G.
    Kleinclauss, F.
    Pivot, X.
    Thiery-Vuillemin, A.
    Limat, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 271 - 271
  • [23] Integrated molecular analysis of clear-cell renal cell carcinoma
    Sato, Yusuke
    Yoshizato, Tetsuichi
    Shiraishi, Yuichi
    Maekawa, Shigekatsu
    Okuno, Yusuke
    Kamura, Takumi
    Shimamura, Teppei
    Sato-Otsubo, Aiko
    Nagae, Genta
    Suzuki, Hiromichi
    Nagata, Yasunobu
    Yoshida, Kenichi
    Kon, Ayana
    Suzuki, Yutaka
    Chiba, Kenichi
    Tanaka, Hiroko
    Niida, Atsushi
    Fujimoto, Akihiro
    Tsunoda, Tatsuhiko
    Morikawa, Teppei
    Maeda, Daichi
    Kume, Haruki
    Sugano, Sumio
    Fukayama, Masashi
    Aburatani, Hiroyuki
    Sanada, Masashi
    Miyano, Satoru
    Homma, Yukio
    Ogawa, Seishi
    NATURE GENETICS, 2013, 45 (08) : 860 - U191
  • [24] Dystroglycan expression in clear-cell type renal cell carcinoma
    Camerini, A.
    De Luca, F.
    Genovese, G.
    De Paola, B.
    Valsuani, C.
    Tartarelli, G.
    Donati, S.
    Rettino, A.
    Cittadini, A.
    Sgambato, A.
    Gentili, C.
    Amoroso, D.
    ANNALS OF ONCOLOGY, 2006, 17 : XI34 - XI35
  • [25] Sorafenib in advanced clear-cell renal-cell carcinoma
    Escudier, Bernard
    Eisen, Tim
    Stadler, Walter M.
    Szczylik, Cezary
    Oudard, Stephane
    Siebels, Michael
    Negrier, Sylvie
    Chevreau, Christine
    Solska, Ewa
    Desai, Apurva A.
    Rolland, Frederic
    Demkow, Tomasz
    Hutson, Thomas E.
    Gore, Martin
    Freeman, Scott
    Schwartz, Brian
    Shan, Minghua
    Simantov, Ronit
    Bukowski, Ronald M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02): : 125 - 134
  • [26] BILATERAL SYNCHRONOUS MULTIFOCAL RENAL CLEAR-CELL CARCINOMA
    Pothen, L.
    Rouviere, H.
    Sleiman, Bou W.
    Aydin, S.
    Feyaerts, A.
    Nica, M-, I
    Lambert, M.
    ACTA CLINICA BELGICA, 2013, 68 (01) : 75 - 76
  • [27] THYROID METASTASIS OF CLEAR-CELL RENAL-CARCINOMA
    LEHUR, PA
    COTE, RA
    POISSON, J
    BOCTOR, M
    ELHILALI, M
    KANDALAFT, N
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1983, 128 (02) : 154 - 156
  • [28] Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
    Ricketts, Christopher J.
    Crooks, Daniel R.
    Linehan, W. Marston
    CANCER CELL, 2016, 30 (04) : 515 - 517
  • [29] Novel treatment strategies in clear-cell metastatic renal cell carcinoma
    van Spronsen, DJ
    de Weijer, KJM
    Mulders, PFA
    De Mulder, RHM
    ANTI-CANCER DRUGS, 2005, 16 (07) : 709 - 717
  • [30] Molecular profile of sunitinib resistance in clear-cell renal cell carcinoma
    Torras, Oscar Reig
    Marin-Aguilera, Mercedes
    Jimenez, Natalia
    Laia, Pare
    Galvan, Patricia
    Mallofre, Carme
    Prat, Aleix
    Mellado, Begona
    CANCER RESEARCH, 2017, 77